Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Mallinckrodt Plc Ordinary Share (MNK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,657,929
  • Shares Outstanding, K 83,313
  • Annual Sales, $ 3,222 M
  • Annual Income, $ 2,134 M
  • 36-Month Beta 1.90
  • Price/Sales 0.53
  • Price/Cash Flow 1.23
  • Price/Book 0.25

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate 1.91
  • Number of Estimates 9
  • High Estimate 1.96
  • Low Estimate 1.86
  • Prior Year 2.01
  • Growth Rate Est. (year over year) -4.98%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.18 +35.90%
on 12/27/18
20.65 -0.10%
on 01/18/19
+1.96 (+10.50%)
since 12/18/18
3-Month
15.18 +35.90%
on 12/27/18
32.34 -36.21%
on 11/13/18
-6.57 (-24.15%)
since 10/18/18
52-Week
11.65 +77.08%
on 05/04/18
36.65 -43.71%
on 08/20/18
-1.07 (-4.93%)
since 01/18/18

Most Recent Stories

More News
Mallinckrodt plc To Report Earnings Results For Fourth Quarter And Fiscal 2018

Mallinckrodt Pharmaceuticals (NYSE: MNK), a leading global specialty pharmaceutical company, announced today that it will report fourth quarter and fiscal 2018 earnings results for the period ending Dec....

MNK : 20.63 (+3.67%)
MNK vs. AMPH: Which Stock Should Value Investors Buy Now?

MNK vs. AMPH: Which Stock Is the Better Value Option?

AMPH : 21.94 (-0.63%)
MNK : 20.63 (+3.67%)
Akorn (AKRX) Gets FDA Warning Letter for Illinois Facility

Akorn, Inc. (AKRX) suffers a setback with the FDA handing over a warning letter post an inspection of its Illinois manufacturing facility in April and May of 2018.

MYL : 29.59 (+0.14%)
RDY : 37.04 (-0.70%)
MNK : 20.63 (+3.67%)
AKRX : 3.59 (unch)
Cara (CARA) Up on IDMC's Recommendation to Continue Trial

Cara (CARA) gains after IDMC recommended the late-stage trial on lead drug, Korsuva, to continue without any modifications.

CARA : 15.35 (-0.26%)
MNK : 20.63 (+3.67%)
PCRX : 40.04 (+3.38%)
FMS : 35.15 (+0.83%)
Mallinckrodt Has Returned 38.8% Since SmarTrend Recommendation (MNK)

SmarTrend identified a Downtrend for Mallinckrodt (NYSE:MNK) on November 21st, 2018 at $27.36. In approximately 1 month, Mallinckrodt has returned 38.77% as of today's recent price of $16.75.

MNK : 20.63 (+3.67%)
Data on Use of Mallinckrodt's H.P. Acthar® Gel (Repository Corticotropin Injection) in Patients with Rare Cause of Nephrotic Syndrome Published in Transplantation

Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today announced publication of a retrospective analysis assessing the efficacy of H.P. Acthar® Gel (repository corticotropin...

MNK : 20.63 (+3.67%)
Heron Gains on Priority Review Designation for Pain Drug

Heron (HRTX) soars after the FDA accepted the company's NDA for pain drug, HTX-011, and granted Priority Review designation to the application.

ENDP : 9.70 (-1.52%)
MNK : 20.63 (+3.67%)
BMY : 50.12 (+1.05%)
HRTX : 27.03 (+0.90%)
Downtrend Call Working As Mallinckrodt Stock Falls 38.9% (MNK)

SmarTrend identified a Downtrend for Mallinckrodt (NYSE:MNK) on November 21st, 2018 at $27.36. In approximately 1 month, Mallinckrodt has returned 38.91% as of today's recent price of $16.71.

MNK : 20.63 (+3.67%)
MNK February 2019 Options Begin Trading

Investors in Mallinckrodt plc saw new options become available today, for the February 2019 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MNK options chain...

MNK : 20.63 (+3.67%)
Mallinckrodt's Inhaled Xenon Gas Therapy Enters Phase III

Mallinckrodt (MNK) and partner NPXe Limited enrol the first patient in the phase III study on xenon gas for inhalation (XENEX) for Post Cardiac Arrest Syndrome (PCAS).

MDCO : 20.00 (+0.25%)
BAX : 70.63 (+2.18%)
GILD : 69.18 (+0.77%)
MNK : 20.63 (+3.67%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

See More Share

Trade MNK with:

Business Summary

Mallinckrodt Plc. is engaged in pharmaceuticals business. It develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. The company's Specialty Pharmaceuticals segment includes branded and generic drugs and Medical Imaging segment includes contrast media...

See More

Key Turning Points

2nd Resistance Point 21.24
1st Resistance Point 20.94
Last Price 20.63
1st Support Level 20.04
2nd Support Level 19.44

See More

52-Week High 36.65
Fibonacci 61.8% 27.10
Fibonacci 50% 24.15
Fibonacci 38.2% 21.20
Last Price 20.63
52-Week Low 11.65

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar